Vietnamese Pharmaceutical Industry

Following the article on investment restrictions in the pharmaceutical industry

Capital Requirements for Business Activities

Vietnam imposes different capital requirements based on the type of pharmaceutical activity:

These requirements are subject to change and may vary depending on location and specific product categories.

Business Activities Minimum Capital Requirements (2025)
Manufacturing (Basic) 25 billion VND (~1.1 million USD)
Production (Specialized) 35 billion VND (~1.5 million USD)
Wholesale Distribution 10 billion VND (~430,000 USD)
Retail Operations 5 billion VND (~215,000 USD)
Import-Export Operations 15 billion VND (~645,000 USD)

Activities Exclusive to Domestic Businesses

Certain pharmaceutical activities remain exclusive to Vietnamese entities:

  • Direct procurement of pharmaceuticals for public hospitals and clinics
  • Distribution of certain essential medicines under national programs
  • Operating pharmaceutical retail outlets in remote areas or economically disadvantaged regions
  • Direct-to-consumer advertising of pharmaceuticals in Vietnam
  • Certain drug registration processes without local partnerships

Case Study: Impact of Restrictions on Foreign Companies

Case Study 1: Novartis Vietnam

In 2023, Novartis sought to expand its direct distribution network in Vietnam but encountered significant obstacles due to a 49% ownership limit. The company ultimately established a complex agreement with a local pharmaceutical distributor, maintaining operational control through management agreements while technically complying with ownership restrictions.

Scenario 2: South Korean Pharmaceutical Manufacturer

A leading South Korean pharmaceutical company established a 100% foreign-owned manufacturing facility in 2024 but encountered unforeseen restrictions when attempting to distribute products directly to hospitals. The company was required to establish a separate joint venture with a local partner for distribution activities, increasing operational costs and complexity.

Strategic Approaches to Overcome Restrictions

Effective Joint Venture Structures

Due to ownership restrictions, strategic joint ventures remain the most viable approach for comprehensive market entry. Successful structures include:

  • Production-focused joint venture: Establish 100% foreign-owned production operations while partnering with Vietnamese distributors to access the market
  • Two-entity structure: Creating separate legal entities for different activities (production vs. distribution) with varying ownership ratios
  • Technology-focused partnerships: Leveraging technology transfer agreements to secure preferential treatment while maintaining intellectual property protection
  • Phased investment approach: Start with a minority stake and gradually increase ownership as relationships with regulatory authorities are strengthened
  • Trade authorization registration: Register drugs for distribution in Vietnam through a distributor or exclusive agent in Vietnam

Key factors for successful joint ventures include thorough partner due diligence, clear governance structures, and well-defined operational control agreements.

Alternative Investment Structures

In addition to traditional joint ventures, alternative approaches include:

  • Strategic M&A: Acquiring minority stakes in established Vietnamese pharmaceutical companies with existing licenses and distribution networks
  • Licensing agreements: Granting technology and product licenses to Vietnamese manufacturers while maintaining brand control
  • Contract manufacturing agreements: Utilizing Vietnamese manufacturers for production while focusing on marketing and distribution
  • Research and Development Partnerships: Establish R&D centers eligible for investment incentives while building relationships with regulatory authorities

Leveraging Economic Zones and Incentives

Vietnam offers special investment incentives in specific regions that pharmaceutical investors can take advantage of:

  • High-tech zones in Hanoi, Ho Chi Minh City, and Da Nang offer tax incentives for pharmaceutical production
  • Economic zones in Binh Duong and Dong Nai offer streamlined administrative procedures
  • Specialized pharmaceutical industrial clusters are being developed with enhanced infrastructure
  • Projects related to advanced technology or meeting specific export thresholds are eligible for additional tax benefits

Strategic Market Entry Procedures

The sequence of market entry activities significantly impacts success rates:

  • Phase 1: Establish a representative office to build relationships and gain market understanding
  • Phase 2: Develop production capacity through a 100% foreign-owned entity or strategic joint venture
  • Phase 3: Establish distribution partnerships with established local entities
  • Phase 4: Gradually expand into retail and direct marketing when regulations permit

Compliance with Regulations and Documentation

Essential Documents for Investment Approval

A successful pharmaceutical investment dossier requires comprehensive documentation:

  • Investment Registration Certificate (IRC): The foundational document enabling foreign investment activities
  • Enterprise Registration Certificate (ERC): Required to establish a legal business entity
  • Pharmaceutical Business License: Specific to pharmaceutical activities
  • Good Practice Certificates: Including GMP, GSP, GDP, GPP depending on the activity
  • Product Registration File: For each pharmaceutical product to be manufactured or distributed
  • Environmental Impact Assessment: Specifically for manufacturing activities

Each document requires specific supporting documents and approval from different regulatory authorities.

Procedures and Timelines for Licensing

Understanding the procedure timeline is crucial for project planning:

Approval Process Official Time Actual Time
Investment Registration Certificate 15-45 days 2-4 months
Business Registration Certificate 3-5 working days 2–3 weeks
Pharmaceutical business license 30 days 2–6 months
GMP/GDP certification 30 days for inspection 3–6 months total
Product registration 12 months 12–24 months

These timelines may be affected by the completeness of documentation, relationships with regulatory authorities, and the complexity of the project.

Common Compliance Issues

Foreign investors often face challenges in the following areas:

  • Inconsistent documentation: Differences between business scope descriptions in different permits
  • Incomplete technical documentation: Especially data confirming production processes and product stability
  • Insufficient attention to environmental requirements: Especially for manufacturing activities
  • Underestimating personnel requirements: Especially regarding certified Vietnamese pharmacists
  • Failure to comply post-licensing: Lack of mandatory periodic reports or inspection requirements

Successfully navigating the regulatory environment requires:

  • Establishing early relationships with key regulatory officials
  • Hiring experienced local pharmaceutical regulatory consultants
  • Maintain regular communication with the licensing authority
  • Participate in industry associations to stay updated on regulatory changes
  • Conducting pre-submission consultations for complex applications

Future Outlook and Regulatory Trends

Upcoming Regulatory Changes

Some upcoming regulatory developments will impact pharmaceutical investments:

  • Expected revisions to the Drug Registration Circular by the end of 2025
  • Revised regulations on pharmaceutical price controls affecting profit models
  • Possibility of adjusting foreign ownership limits in wholesale distribution (draft proposal suggests increasing to 51%)
  • New regulations on electronic pharmaceuticals and digital health services are under development
  • Enhanced requirements for pharmaceutical traceability and anti-counterfeiting measures

Impact of International Trade Agreements

Recent and upcoming trade agreements are reshaping the investment environment:

  • CPTPP: Provides stronger intellectual property protection and gradual liberalization of certain pharmaceutical services
  • EVFTA: Includes provisions on regulatory cooperation and potential increased investment opportunities for European pharmaceutical companies
  • RCEP: Creates opportunities for regional supply chain integration in pharmaceutical production

While these agreements signal Vietnam’s commitment to further opening its market, the implementation of pharmaceutical provisions typically takes time, with significant transition periods.

Expert Forecasts on Investment Liberalization

Industry experts and regulatory analysts predict:

  • Gradual increase in ownership limits for wholesale distribution to 51-74% by 2027
  • Continued protection of retail pharmacy operations with minimal liberalization
  • Additional incentives for high-tech pharmaceutical production and R&D
  • Simplified product registration procedures for certain priority drugs
  • The ability to create special regulatory pathways for innovative therapies and biosimilar drugs

Opportunities in Vietnam’s Healthcare Development

Despite limitations, significant opportunities are emerging from Vietnam’s healthcare development:

  • Expanding hospital infrastructure is driving demand for specialized pharmaceutical products
  • The growing middle class is driving the development of the premium pharmaceutical segment
  • Expanding national health insurance increases access to pharmaceuticals
  • Digital healthcare transformation creates opportunities for innovative distribution models
  • Developing clinical research capabilities support new product development

Conclusion

Summary of Key Investment Constraints

Foreign pharmaceutical investors in Vietnam face a complex and restrictive system that varies significantly depending on business activities:

  • Manufacturing activities offer the most liberal investment environment, allowing up to 100% foreign ownership
  • Distribution and wholesale activities are subject to a 49% foreign ownership limit and operational restrictions
  • Participation in pharmaceutical retail remains strictly restricted, with both ownership and operational limits
  • All pharmaceutical activities require specific licenses, certifications, and ongoing compliance obligations

Strategic Recommendations

For foreign pharmaceutical companies considering entering the Vietnamese market, recommended approaches include:

  • Implement a phased market entry strategy, starting with authorized manufacturing or distribution
  • Conduct thorough due diligence on potential Vietnamese partners, focusing on relationships with regulatory authorities and compliance history
  • Develop flexible business models that can adapt to evolving legal requirements
  • Invest in developing relationships with key regulatory agencies
  • Participate in policy dialogues through industry associations to influence future regulatory directions

Balance Compliance and Business Objectives

Navigating the Vietnamese pharmaceutical industry successfully requires a balance between strict regulatory compliance and commercial objectives. Foreign investors should:

  • Maintain transparent compliance with all ownership restrictions while optimizing operational influence through management agreements
  • Develop comprehensive regulatory strategies in parallel with business plans, recognizing that regulatory approvals often determine market success
  • Leverage Vietnam’s increasing emphasis on pharmaceutical self-sufficiency by aligning investments with national healthcare priorities
  • Prepare for a long-term market presence, as successful pharmaceutical operations in Vietnam typically require 5-7 years to achieve profitability

Although the Vietnamese pharmaceutical market presents significant regulatory challenges for foreign investors, those who navigate these constraints strategically can access a rapidly growing market with significant long-term potential. The key lies in understanding the specific limitations applicable to each business activity and developing approaches that align with both regulatory requirements and commercial objectives.

Need Professional Guidance?

Harley Miller Law Firm provides specialized legal consulting services for pharmaceutical investments in Vietnam, with a team of experts boasting over 15 years of industry experience.

Our Services

  • Investment strategy consulting: Analyzing legal restrictions and proposing suitable investment structures
  • Licensing support: Comprehensive guidance on the process of obtaining Investment Certificates and Pharmaceutical Business Licenses
  • Legal due diligence: Evaluating potential partners and associated legal risks
  • Business establishment: Assisting in the establishment of subsidiaries, representative offices, or joint ventures
  • Compliance: Consulting on GMP, GSP, GDP, and other good practice standards

Why Choose Harley Miller Law Firm?

  • A team of lawyers specializing in pharmaceuticals and foreign investment law in Vietnam
  • Experience in assisting international pharmaceutical companies enter the Vietnamese market
  • A practical approach to help clients navigate complex legal challenges
  • In-depth understanding of future regulatory trends and new investment opportunities

Contact us today for a consultation on your pharmaceutical investment strategy in Vietnam. Our team of experts is ready to assist you in developing compliant and commercially viable approaches to this promising market.

Email: [email protected]

Phone: +84 937215585

See our latest News

Mark Benton

Litigation in Korea – Part 1

September 8, 2025

Sameer Khan

Entrepreneur’s Guide to Structuring Successful Mergers an...

September 8, 2025

Sameer Khan

Entrepreneur’s Guide to Structuring Successful Mergers an...

September 8, 2025

Sameer Khan

Your Guide to DIFC Employment Rights and Law 2025

September 8, 2025

Alicea Castellanos

LOS EXPATRIADOS DEBEN ANALIZAR EL PAISAJE FISCAL ANTES DE...

September 3, 2025

Alicea Castellanos

EXPATS MUST SURVEY THE TAX LANDSCAPE BEFORE THEY JUMP INT...

September 3, 2025

Leith Ben Ammar

Greenberg Traurig, LLP’s London office won the award for ...

September 2, 2025

Leith Ben Ammar

Greenberg Traurig Shortlisted for 4 Legal Business Awards

September 2, 2025

Leith Ben Ammar

LCAM’s Blockchain Expedited Arbitration Rules, Developed ...

September 2, 2025

Sushila Ram Varma

INDIAN COURTS REINFORCE ARBITRATORS AUTONOMY

September 2, 2025